American Association for Cancer Research
Browse
epi-22-0590_figure_s3_suppsf3.pdf (1.57 MB)

Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer

Download (1.57 MB)
journal contribution
posted on 2023-05-23, 14:00 authored by Andrea Walens, Sarah C. Van Alsten, Linnea T. Olsson, Markia A. Smith, Alex Lockhart, Xiaohua Gao, Alina M. Hamilton, Erin L. Kirk, Michael I. Love, Gaorav P. Gupta, Charles M. Perou, Cyrus Vaziri, Katherine A. Hoadley, Melissa A. Troester
Supplementary Figure from RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer

Funding

Susan G. Komen (SGK)

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill (UNC Lineberger Comprehensive Cancer Center)

History

ARTICLE ABSTRACT

Aberrant expression of DNA repair pathways such as homologous recombination (HR) can lead to DNA repair imbalance, genomic instability, and altered chemotherapy response. DNA repair imbalance may predict prognosis, but variation in DNA repair in diverse cohorts of breast cancer patients is understudied. To identify RNA-based patterns of DNA repair expression, we performed unsupervised clustering on 51 DNA repair-related genes in the Cancer Genome Atlas Breast Cancer [TCGA BRCA (n = 1,094)] and Carolina Breast Cancer Study [CBCS (n = 1,461)]. Using published DNA-based HR deficiency (HRD) scores (high-HRD ≥ 42) from TCGA, we trained an RNA-based supervised classifier. Unsupervised and supervised HRD classifiers were evaluated in association with demographics, tumor characteristics, and clinical outcomes. : Unsupervised clustering on DNA repair genes identified four clusters of breast tumors, with one group having high expression of HR genes. Approximately 39.7% of CBCS and 29.3% of TCGA breast tumors had this unsupervised high-HRD (U-HRD) profile. A supervised HRD classifier (S-HRD) trained on TCGA had 84% sensitivity and 73% specificity to detect HRD-high samples. Both U-HRD and S-HRD tumors in CBCS had higher frequency of TP53 mutant-like status (45% and 41% enrichment) and basal-like subtype (63% and 58% enrichment). S-HRD high was more common among black patients. Among chemotherapy-treated participants, recurrence was associated with S-HRD high (HR: 2.38, 95% confidence interval = 1.50–3.78). HRD is associated with poor prognosis and enriched in the tumors of black women. RNA-level indicators of HRD are predictive of breast cancer outcomes in diverse populations.

Usage metrics

    Cancer Epidemiology, Biomarkers & Prevention

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC